$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Biomarin Pharmaceutical (BMRN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~14.9%/yr (FY21→FY25), net margin 10.8%, and free cash flow (~$725.0M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+8.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲12.9%
3,221.3
FY21→FY25CAGR +14.9%/yr
Net income ($M)▼18.3%
348.9
one-off year: see footnoteCAGR +35.1%/yr
Free cash flow ($M)▲48.7%
725.0
FY21→FY25CAGR +36.5%/yr
Diluted EPS▼18.6%
1.80
FY22→FY25CAGR +33.9%/yr
What the receipts whisper · what a headline number hides
Share count
+8.0%
182.9mn → 197.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$103.0M
+20.6% YoY in FY25 · 3.2% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
11¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 74.5% → 77.7%. Net margin 10.8% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,655.1 | 3,221.3 | 2,853.9 | 2,419.2 | 2,096.0 | 1,846.3 | ▲12.9% | +14.9% |
Cost of revenue | 878.9 | 717.4 | 580.2 | 532.1 | 503.0 | 470.5 | ▲23.6% | +11.1% |
Gross profit | 2,776.2 | 2,503.8 | 2,273.7 | 1,887.2 | 1,593.0 | 1,375.8 | ▲10.1% | +16.1% |
Research & development | 1,046.4 | 921.9 | 747.2 | 746.8 | 649.6 | 628.8 | ▲23.4% | +10.0% |
Selling, general & admin | 1,433.7 | 1,153.0 | 1,009.0 | 892.4 | 823.2 | 759.4 | ▲14.3% | +11.0% |
Total operating expenses | 2,662.3 | 2,094.3 | 1,789.5 | 1,701.4 | 1,432.0 | 1,458.1 | ▲17.0% | +9.5% |
Operating incomefeeds ROC rank | 113.9 | 409.5 | 484.2 | 185.8 | 161.0 | −82.3 | ▼15.4% | +36.5% (22→25) |
Other income, net | −70.2 | 73.0 | 57.5 | 2.8 | −11.4 | 7.0 | — | — |
Pretax income | 43.7 | 482.5 | 541.8 | 188.6 | 149.6 | −75.3 | ▼10.9% | +47.8% (22→25) |
Income tax | 62.8 | 133.6 | 114.9 | 20.9 | 8.0 | −11.3 | ▲16.3% | +155.4% (22→25) |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | −19.1 | 348.9 | 426.9 | 167.6 | 141.6 | −64.1 | ▼18.3% | +35.1% (22→25) |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.08 | 1.80 | 2.21 | 0.87 | 0.75 | −0.35 | ▼18.6% | +33.9% (22→25) |
Diluted shares (mn) | 193.59 | 197.39 | 196.71 | 191.59 | 188.96 | 182.85 | ▲0.3% | +1.9% |
| Margins | ||||||||
Gross margin69th pct in Healthcare | 76.0% | 77.7% | 79.7% | 78.0% | 76.0% | 74.5% | ▼1.9pp | +3.2pp |
Operating margin | 3.1% | 12.7% | 17.0% | 7.7% | 7.7% | −4.5% | ▼4.3pp | +17.2pp |
Net margin38th pct in Healthcare | −0.5% | 10.8% | 15.0% | 6.9% | 6.8% | −3.5% | ▼4.1pp | +14.3pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 5% vs a 15% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 28% vs a 15% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Biomarin Pharmaceutical's revenue last fiscal year?
Biomarin Pharmaceutical reported revenue of $3,221.3M in fiscal 2025, up 12.9% from fiscal 2024.
What was Biomarin Pharmaceutical's net income?
Biomarin Pharmaceutical reported net income of $348.9M in fiscal 2025, a net margin of 10.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

